Literature DB >> 23109013

Candidemia: species involved, virulence factors and antimycotic susceptibility.

Concetta De Luca1, Maria Guglielminetti, Antonella Ferrario, Maria Calabr, Erminia Casari.   

Abstract

We investigate the characteristics of the Candida species involved in BSI episodes in our Institute, their phospholipase and protease activity and the susceptibility pattern towards the main antifungal agents currently available. From January 2009 to December 2010 we documented a total of 59 episodes of candidemia. The incidence of candidemia was 32% in General Surgery, 22% in the Intensive Care Unit (ICU), 13% in Oncology and 10% in Gastroenterology. C. albicans was the most common species (32 cases=48%), followed by C. glabrata (17 cases=26%) and C. parapsilosis (12 cases=18%), a significant production of phospholipase in all strains of C. albicans was detected. Among Candida non-albicans species, the production of this enzyme only occurred in 1/12 strains of C. parapsilosis. The expression acid protease production was detected in 48% of C. albicans and no strains of Candida non-albicans. All species of Candida were susceptible to amphotericin B. The rate of susceptibility to fluconazole was 100% for albicans and C. parapsilosis. Decreased susceptibility to fluconazole was mostly seen with C. glabrata, which was 76.5% susceptible in a dose-dependent manner. The echinocandins showed a good performance for C. albicans, and maintained a good MIC distribution in C. glabrata.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109013

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  12 in total

1.  Sub-inhibitory concentrations of antifungals suppress hemolysin activity of oral Candida albicans and Candida tropicalis isolates from HIV-infected individuals.

Authors:  Sukumaran Anil; Mohamed Hashem; Sajith Vellappally; Shankargouda Patil; H M H N Bandara; L P Samaranayake
Journal:  Mycopathologia       Date:  2014-08-21       Impact factor: 2.574

2.  Oral mucositis caused by Candida glabrata biofilms: failure of the concomitant use of fluconazole and ascorbic acid.

Authors:  Célia F Rodrigues; Mariana Henriques
Journal:  Ther Adv Infect Dis       Date:  2017-02-17

3.  The Effectiveness of Voriconazole in Therapy of Candida glabrata's Biofilms Oral Infections and Its Influence on the Matrix Composition and Gene Expression.

Authors:  Célia F Rodrigues; Bruna Gonçalves; Maria Elisa Rodrigues; Sónia Silva; Joana Azeredo; Mariana Henriques
Journal:  Mycopathologia       Date:  2017-04-24       Impact factor: 2.574

4.  Effect of Voriconazole on Candida tropicalis Biofilms: Relation with ERG Genes Expression.

Authors:  Tânia Fernandes; Sónia Silva; Mariana Henriques
Journal:  Mycopathologia       Date:  2016-06-03       Impact factor: 2.574

5.  Antifungal susceptibility and phenotypic virulence markers of Candida species isolated from Nepal.

Authors:  Supram Hosuru Subramanya; Bharat Prasad Baral; Nawal Kishor Sharan; Niranjan Nayak; Yang Metok; Brijesh Sathian; Indira Bairy; Shishir Gokhale
Journal:  BMC Res Notes       Date:  2017-11-02

6.  Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms.

Authors:  Célia F Rodrigues; Diana F Alves; Mariana Henriques
Journal:  Microorganisms       Date:  2018-12-04

7.  Periprosthetic Fungal Infections in Severe Endoprosthetic Infections of the Hip and Knee Joint-A Retrospective Analysis of a Certified Arthroplasty Centre of Excellence.

Authors:  Andreas Enz; Silke C Mueller; Philipp Warnke; Martin Ellenrieder; Wolfram Mittelmeier; Annett Klinder
Journal:  J Fungi (Basel)       Date:  2021-05-21

8.  Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013.

Authors:  Yoshiaki Kamikawa; Youichirou Mori; Tomohiro Nagayama; Junichi Fujisaki; Daisuke Hirabayashi; Ryoichi Sakamoto; Tomofumi Hamada; Kazumasa Sugihara
Journal:  BMC Oral Health       Date:  2014-02-20       Impact factor: 2.757

9.  Effect of Delta-9-tetrahydrocannabinol on mouse resistance to systemic Candida albicans infection.

Authors:  Gideon W Blumstein; Arya Parsa; Anthony K Park; Beverly L P McDowell; Melissa Arroyo-Mendoza; Marie Girguis; Jill P Adler-Moore; Jon Olson; Nancy E Buckley
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

10.  First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes.

Authors:  Maria Helena Galdino Figueiredo-Carvalho; Livia de Souza Ramos; Leonardo Silva Barbedo; Alessandra Leal da Silva Chaves; Ilda Akemi Muramoto; André Luis Souza dos Santos; Rodrigo Almeida-Paes; Rosely Maria Zancopé-Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-01       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.